Months after Daiichi Sankyo’s announcement to reduce its workforce in the US by half in a bid to revive business, the Japanese pharma major, on December 1, 2015, decided to close its German research subsidiary, U3 Pharma GmbH.
Daiichi Sankyo intends to strengthen its global research and development capabilities by increasing efficiency and streamlining processes. Based on this objective, the global R&D capacities have been reviewed and the Company has decided to concentrate core research functions of Daiichi Sankyo Group in future.
U3, with about 40 employees and which is engaged in research and development work on antibody targeting for cancer treatments, will transfer its current research and development tasks to the Biologics Function in Tokyo.
